NK News and Press, NantKwest From 12/30/20

NEW YORK, NY / ACCESSWIRE / December 30, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: NantKwest, Inc. (NASDAQ: NK ) relating to i...

In our bodies we have cancer-killer cells called "natural killer" cells, or NK cells. These cells are part of our innate immune system. When an NK cell comes across a malign cancer cell in the human body, the NK cell attacks it and destroys it. Scientists believe that this natural cance...

WeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing Investigations PR Newswire NEW YORK , Dec. 29, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigatio...

HEXO (HEXO) -74% Soligenix SNGX -51% as SGX942 flunks oral mucositis study in cancer patients.Forward Industries (FORD) -15%.Venus Concept VERO -16% on announcing public offering.Exicure XCUR -14% on announcing issuance of two new U.S. patents, and new ...

Shares of the cancer immunotherapy company NantKwest (NASDAQ: NK) are up by a healthy 36.6% as of 11:20 a.m. EST Monday morning. The biotech's shares are moving north today for two key reasons: Image source: Getty Images. Prior to this merger agreement, NantKwest's quest to ...

Gainers: Anterix (ATEX) +67%.NantKwest (NK) +55%.500.com Limited (WBAI) +51%.Editas Medicine (EDIT) +47%.EyeGate Pharmaceuticals (EYEG) +45%.Organovo Holdings (ONVO) +36%.Nuverra Environmental Solutions (NES) +33%.RealPage (RP) +29%.Agios Pharmaceuticals (AGIO) +29%.CuriosityStream (CURI...

Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...

EyeGate Pharmaceuticals (EYEG) +87% as it acquires Panoptes Pharma.NantKwest (NK) +32% as its partner, ImmunityBio, achieves primary endpoint in bladder cancer study.RealPage (RP) +31% as Thoma Bravo has agreed to buy the company for $9.6B.China Customer Relations Centers (CCRC...

NantKwest surges 61% premarket after its partner ImmunityBio announces positive data from the first cohort of a Phase 2/3 trial (QUILT 3.032) of IL-15 fusion protein, Anktiva, for non-muscle invasive bladder cancer in high risk carcinoma in situ ((CIS)) disease.The da...

NantKwest (NK), up 21% premarket and privately-held ImmunityBio and NantKwest (NK) have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease. Together, Im...